Clinical use of fluoroquinolones in children

OBJECTIVE: To review the pharmacokinetics, efficacy, and safety of fluoroquinolones in children. DATA SOURCES: A MEDLINE search (January 1966-March 1998) was conducted for relevant literature. STUDY SELECTION AND DATA EXTRACTION: Data from compassionate use and published studies were reviewed for the assessment of pharmacokinetics, efficacy, and safety of fluoroquinolones in children. DATA SYNTHESIS: Fluoroquinolones have a broad spectrum coverage of gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa and intracellular organisms. Fluoroquinolones are well absorbed from the gastrointestinal tract, have excellent tissue penetration, low protein binding, and long elimination half-lives. These antibiotics are effective in treating various infections and are well tolerated in adults. However, the use of fluoroquinolones in children has been restricted due to potential cartilage damage that occurred in research with immature animals. Fluoroquinolones have been used in children on a compassionate basis. Ciprofloxacin is the most frequently used fluoroquinolone in children, most often in the treatment of pulmonary infection in cystic fibrosis as well as salmonellosis and shigellosis. Other uses include chronic suppurative otitis media, meningitis, septicemia, and urinary tract infection. Safety data of fluoroquinolones in children appear to be similar to those in adults. Fluoroquinolones are associated with tendinitis and reversible arthralgia in adults and children. However, direct association between fluoroquinolones and arthropathy remains uncertain. CONCLUSIONS: Fluoroquinolones have been found to be effective in treating certain infections in children. Additional research is needed to define the optimal dosage regimens in pediatric patients. Although fluoroquinolones appear to be well tolerated, further investigations are needed to determine the risk of arthropathy in children. However, their use in children should not be withheld when the benefits outweigh the risks.

This article has been cited by other articles:

				P. C. Drobac, J. S. Mukherjee, J. K. Joseph, C. Mitnick, J. J. Furin, H. del Castillo, S. S. Shin, and M. C. Becerra Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics, June 1, 2006; 117(6): 2022 - 2029. [Abstract] [Full Text] [PDF]

				S. Chien, T. G. Wells, J. L. Blumer, G. L. Kearns, J. S. Bradley, J. A. Bocchini Jr, J. Natarajan, S. Maldonado, and G. J. Noel Levofloxacin Pharmacokinetics in Children J. Clin. Pharmacol., February 1, 2005; 45(2): 153 - 160. [Abstract] [Full Text] [PDF]

				S. Payen, R. Serreau, A. Munck, Y. Aujard, Y. Aigrain, F. Bressolle, and E. Jacqz-Aigrain Population Pharmacokinetics of Ciprofloxacin in Pediatric and Adolescent Patients with Acute Infections Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3170 - 3178. [Abstract] [Full Text] [PDF]

				C. Roberts Comparison of the Ocular Comfort of Ofloxacin 0.3% Ophthalmic Solution and Lubricant Eye Drops Clinical Pediatrics, April 1, 2002; 41(3): 151 - 154. [PDF]

				A. M. Levine and J. R. DiBona Fluoroquinolones J. Am. Acad. Ortho. Surg., January 1, 2002; 10(1): 1 - 4. [Full Text] [PDF]

				K. G. Chin, C. E. McPherson III, M. Hoffman, A. Kuchta, and C. Mactal-Haaf Use of Anti-Infective Agents During Lactation: Part 2--Aminoglycosides, Macrolides, Quinolones, Sulfonamides, Trimethoprim, Tetracyclines, Chloramphenicol, Clindamycin, and Metronidazole J Hum Lact, February 1, 2001; 17(1): 54 - 65. [Abstract] [PDF]